Mayank Mamtani
Stock Analyst at B. Riley Securities
(4.47)
# 294
Out of 4,920 analysts
126
Total ratings
45.45%
Success rate
35.61%
Average return
Main Sectors:
Stocks Rated by Mayank Mamtani
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NKTR Nektar Therapeutics | Maintains: Buy | $60 → $85 | $23.27 | +265.28% | 2 | Jul 8, 2025 | |
| MNOV MediciNova | Maintains: Buy | $6 → $5 | $1.35 | +270.37% | 2 | Jun 16, 2025 | |
| MGNX MacroGenics | Maintains: Neutral | $5 → $3 | $1.64 | +82.93% | 2 | May 20, 2025 | |
| MDGL Madrigal Pharmaceuticals | Reiterates: Buy | $422 → $460 | $312.11 | +47.38% | 12 | May 2, 2025 | |
| HROW Harrow | Maintains: Buy | $69 → $65 | $33.42 | +94.49% | 2 | Apr 1, 2025 | |
| VXRT Vaxart | Maintains: Buy | $2.5 → $2 | $0.37 | +440.69% | 6 | Mar 27, 2025 | |
| TRVI Trevi Therapeutics | Reiterates: Buy | $11 → $20 | $7.48 | +167.56% | 3 | Mar 19, 2025 | |
| LCTX Lineage Cell Therapeutics | Maintains: Buy | $4 → $3 | $0.97 | +209.28% | 2 | Mar 14, 2025 | |
| DNLI Denali Therapeutics | Reiterates: Buy | $38 → $35 | $14.44 | +142.38% | 2 | Mar 5, 2025 | |
| ARWR Arrowhead Pharmaceuticals | Reiterates: Buy | $51 → $38 | $16.47 | +130.79% | 7 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $109 → $96 | $33.98 | +182.52% | 2 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $1 → $1.5 | $0.71 | +110.14% | 3 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 → $26 | $6.75 | +285.19% | 19 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33 | $16.08 | +105.22% | 1 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $20 | $3.58 | +458.66% | 9 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $34 | $28.72 | +18.38% | 13 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $122 → $92 | $36.58 | +151.50% | 3 | Jun 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $140 | $14.96 | +835.83% | 1 | Oct 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $90 | $1.58 | +5,596.20% | 5 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $160 | $5.40 | +2,862.96% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $11 → $5 | $1.47 | +240.14% | 3 | Aug 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $58 → $44 | $2.29 | +1,821.40% | 4 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $90 | $1.88 | +4,687.23% | 4 | Jul 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 → $7 | $2.86 | +145.18% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9,750 → $4,500 | $1.51 | +297,913.25% | 3 | Jan 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5,000 → $2,700 | $6.00 | +44,900.00% | 2 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $138 → $77 | $12.20 | +531.15% | 2 | Jan 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,980 → $1,440 | $1.63 | +88,243.56% | 3 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $4 | $3.59 | +11.42% | 2 | Apr 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $47 → $39 | $99.26 | -60.71% | 2 | Mar 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $34 | $3.84 | +785.76% | 1 | Mar 13, 2020 |
Nektar Therapeutics
Jul 8, 2025
Maintains: Buy
Price Target: $60 → $85
Current: $23.27
Upside: +265.28%
MediciNova
Jun 16, 2025
Maintains: Buy
Price Target: $6 → $5
Current: $1.35
Upside: +270.37%
MacroGenics
May 20, 2025
Maintains: Neutral
Price Target: $5 → $3
Current: $1.64
Upside: +82.93%
Madrigal Pharmaceuticals
May 2, 2025
Reiterates: Buy
Price Target: $422 → $460
Current: $312.11
Upside: +47.38%
Harrow
Apr 1, 2025
Maintains: Buy
Price Target: $69 → $65
Current: $33.42
Upside: +94.49%
Vaxart
Mar 27, 2025
Maintains: Buy
Price Target: $2.5 → $2
Current: $0.37
Upside: +440.69%
Trevi Therapeutics
Mar 19, 2025
Reiterates: Buy
Price Target: $11 → $20
Current: $7.48
Upside: +167.56%
Lineage Cell Therapeutics
Mar 14, 2025
Maintains: Buy
Price Target: $4 → $3
Current: $0.97
Upside: +209.28%
Denali Therapeutics
Mar 5, 2025
Reiterates: Buy
Price Target: $38 → $35
Current: $14.44
Upside: +142.38%
Arrowhead Pharmaceuticals
Feb 14, 2025
Reiterates: Buy
Price Target: $51 → $38
Current: $16.47
Upside: +130.79%
Feb 7, 2025
Reiterates: Buy
Price Target: $109 → $96
Current: $33.98
Upside: +182.52%
Dec 19, 2024
Upgrades: Buy
Price Target: $1 → $1.5
Current: $0.71
Upside: +110.14%
Oct 10, 2024
Reiterates: Buy
Price Target: $23 → $26
Current: $6.75
Upside: +285.19%
Sep 19, 2024
Initiates: Buy
Price Target: $33
Current: $16.08
Upside: +105.22%
Aug 12, 2024
Reiterates: Buy
Price Target: $20
Current: $3.58
Upside: +458.66%
Aug 7, 2024
Maintains: Buy
Price Target: $29 → $34
Current: $28.72
Upside: +18.38%
Jun 4, 2024
Maintains: Buy
Price Target: $122 → $92
Current: $36.58
Upside: +151.50%
Oct 13, 2023
Initiates: Buy
Price Target: $140
Current: $14.96
Upside: +835.83%
Apr 10, 2023
Maintains: Buy
Price Target: $210 → $90
Current: $1.58
Upside: +5,596.20%
Mar 29, 2023
Reiterates: Buy
Price Target: $160
Current: $5.40
Upside: +2,862.96%
Aug 19, 2022
Downgrades: Neutral
Price Target: $11 → $5
Current: $1.47
Upside: +240.14%
Aug 11, 2022
Maintains: Buy
Price Target: $58 → $44
Current: $2.29
Upside: +1,821.40%
Jul 14, 2022
Maintains: Buy
Price Target: $120 → $90
Current: $1.88
Upside: +4,687.23%
May 24, 2022
Downgrades: Neutral
Price Target: $14 → $7
Current: $2.86
Upside: +145.18%
Jan 24, 2022
Maintains: Buy
Price Target: $9,750 → $4,500
Current: $1.51
Upside: +297,913.25%
Nov 30, 2021
Maintains: Buy
Price Target: $5,000 → $2,700
Current: $6.00
Upside: +44,900.00%
Jan 15, 2021
Downgrades: Neutral
Price Target: $138 → $77
Current: $12.20
Upside: +531.15%
May 22, 2020
Downgrades: Neutral
Price Target: $1,980 → $1,440
Current: $1.63
Upside: +88,243.56%
Apr 3, 2020
Maintains: Buy
Price Target: $8 → $4
Current: $3.59
Upside: +11.42%
Mar 18, 2020
Maintains: Buy
Price Target: $47 → $39
Current: $99.26
Upside: -60.71%
Mar 13, 2020
Maintains: Buy
Price Target: $43 → $34
Current: $3.84
Upside: +785.76%